Cancer Biology

Discussions of New Developments and Updates

Home
About
Topics
SHU Department of Biology

Tag Archives: Neoantigens

Neo-antigen vaccines extend progression-free survival in melanoma

Two companies – Biontech, RNA vaccine and Neon Therapeutics, peptide vaccine – reported very positive results of neo-antigen vaccines in patients with refractory metastatic melanoma. Continue reading →

This entry was posted in active immunotherapy, Checkpoint Inhibitors, Uncategorized, Vaccines and tagged CD4+, CD8+, checkpoint inhibition, melanoma, mutations, neo-antigens, Neoantigens, nivolumab, nonsynonymous mutations, Opdivo, T-helper, Treg on July 12, 2017 by Joseph Gulfo.

Neo-antigens for Cancer Immunotherapy

Two new companies have received substantial funding to pursue neo-antigens for cancer immunotherapy: Gritstone Oncology raised $102MM to pursue lung cancer and Neon Therapeutics raised $55MM to develop neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. Continue reading →

This entry was posted in Checkpoint Inhibitors, Immunology & Immunotherapy, Uncategorized and tagged Gritstone, Keytruda, lung cancer, melanoma, mismatch-repair, Neoantigens, Neon Therapeutics, nivolumab, Opdivo, PD-1, Pembrolizumab on October 28, 2015 by Joseph Gulfo.

Search for:

This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]

Proudly powered by WordPress

Pin It on Pinterest